Literature DB >> 8264799

Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats.

B Kobe1, J Deisenhofer.   

Abstract

Ribonuclease inhibitor is a cytoplasmic protein that tightly binds and inhibits ribonucleases of the pancreatic ribonuclease superfamily. The primary sequence of this inhibitor contains leucine-rich repeats (LRRs); these motifs are present in many proteins that participate in protein-protein interactions and have different functions and cellular locations. In vivo, ribonuclease inhibitor may have a role in the regulation of RNA turnover in mammalian cells and in angiogenesis. To define the structural features of LRR proteins and to understand better the nature of the tight interaction of ribonuclease inhibitor with ribonucleases, we have determined the crystal structure of the porcine inhibitor. To our knowledge, this is the first three-dimensional structure of a protein containing LRRs and represents a new class of alpha/beta protein fold. Individual repeats constitute beta-alpha structural units that probably also occur in other proteins containing LRRs. The non-globular shape of the structure and the exposed face of the parallel beta-sheet may explain why LRRs are used to achieve strong protein-protein interactions. A possible ribonuclease-binding region incorporates the surface formed by the parallel beta-sheet and the beta alpha loops.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8264799     DOI: 10.1038/366751a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  129 in total

1.  Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains.

Authors:  M W Linhoff; J A Harton; D E Cressman; B K Martin; J P Ting
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

2.  The structure of the mRNA export factor TAP reveals a cis arrangement of a non-canonical RNP domain and an LRR domain.

Authors:  E Liker; E Fernandez; E Izaurralde; E Conti
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

Review 3.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 4.  Cancer chemotherapy--ribonucleases to the rescue.

Authors:  P A Leland; R T Raines
Journal:  Chem Biol       Date:  2001-05

5.  Assessment of the ability to model proteins with leucine-rich repeats in light of the latest structural information.

Authors:  Andrey V Kajava; Bostjan Kobe
Journal:  Protein Sci       Date:  2002-05       Impact factor: 6.725

6.  CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.

Authors:  S B Hake; K Masternak; C Kammerbauer; C Janzen; W Reith; V Steimle
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

7.  The specificity of polygalacturonase-inhibiting protein (PGIP): a single amino acid substitution in the solvent-exposed beta-strand/beta-turn region of the leucine-rich repeats (LRRs) confers a new recognition capability.

Authors:  F Leckie; B Mattei; C Capodicasa; A Hemmings; L Nuss; B Aracri; G De Lorenzo; F Cervone
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

8.  Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins.

Authors:  William A Barton; Betty P Liu; Dorothea Tzvetkova; Philip D Jeffrey; Alyson E Fournier; Dinah Sah; Richard Cate; Stephen M Strittmatter; Dimitar B Nikolov
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

9.  Biochemical characterization of the Ran-RanBP1-RanGAP system: are RanBP proteins and the acidic tail of RanGAP required for the Ran-RanGAP GTPase reaction?

Authors:  Michael J Seewald; Astrid Kraemer; Marian Farkasovsky; Carolin Körner; Alfred Wittinghofer; Ingrid R Vetter
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

10.  Selective abolition of pancreatic RNase binding to its inhibitor protein.

Authors:  Kapil Kumar; Michael Brady; Robert Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.